CTCX
Income statement / Annual
Last year (2024), Carmell Therapeutics Corporation's total revenue was $50.32 K,
and the percentage change from the previous year is not available.
In 2024, Carmell Therapeutics Corporation's net income was -$10.37 M.
See Carmell Therapeutics Corporation,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
| Operating Revenue |
$50.32 K |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$6.36 K
|
$124.79 K
|
$242.56 K
|
$0.00
|
| Gross Profit |
$43.96 K
|
-$124.79 K
|
-$242.56 K
|
$0.00
|
| Gross Profit Ratio |
0.87
|
0
|
0
|
0
|
| Research and Development Expenses |
$1.05 M
|
$2.50 M
|
$2.20 M
|
$982.84 K
|
| General & Administrative Expenses |
$3.72 M
|
$0.00
|
$3.22 M
|
$863.33 K
|
| Selling & Marketing Expenses |
$189.32 K
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$3.90 M
|
$2.60 M
|
$3.22 M
|
$863.33 K
|
| Other Expenses |
$83.49 K
|
$0.00
|
$10.92 K
|
$37.38 K
|
| Operating Expenses |
$5.04 M
|
$5.09 M
|
$5.51 M
|
$1.94 M
|
| Cost And Expenses |
$5.05 M
|
$5.22 M
|
$5.51 M
|
$1.94 M
|
| Interest Income |
$0.00
|
$0.00
|
$2.25 M
|
$8.09 K
|
| Interest Expense |
$49.02 K
|
$889.32 K
|
$3.75 M
|
$2.50 M
|
| Depreciation & Amortization |
$197.26 K
|
$124.79 K
|
$242.56 K
|
$242.12 K
|
| EBITDA |
-$560.66 K |
-$15.19 M |
-$5.25 M |
-$1.66 M |
| EBITDA Ratio |
-11.14
|
0
|
0
|
0
|
| Operating Income Ratio |
-99.34
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
-$5.75 M
|
-$10.99 M
|
-$3.54 M
|
-$4.54 M
|
| Income Before Tax |
-$10.75 M
|
-$16.21 M
|
-$9.05 M
|
-$6.48 M
|
| Income Before Tax Ratio |
-213.6
|
0
|
0
|
0
|
| Income Tax Expense |
-$97.28 K
|
-$760.16 K
|
$391.20 K
|
$2.54 M
|
| Net Income |
-$10.37 M
|
-$15.45 M
|
-$9.05 M
|
-$6.48 M
|
| Net Income Ratio |
-206.05
|
0
|
0
|
0
|
| EPS |
-0.5 |
-0.74 |
-0.46 |
-0.33 |
| EPS Diluted |
-0.5 |
-0.74 |
-0.46 |
-0.33 |
| Weighted Average Shares Out |
$20.91 M
|
$20.77 M
|
$19.77 M
|
$19.77 M
|
| Weighted Average Shares Out Diluted |
$20.91 M
|
$20.77 M
|
$19.77 M
|
$19.77 M
|
| Link |
|
|
|
|
